The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb

Journal of Pharmacology and Experimental Therapeutics

Volumn 302, Issue 2, 2002, Pages 672-680

  Coe, Yashu ^a   Haleen, Stephen J ^b   Welch, Kathleen M ^b   Liu, You An ^c   Coceani, Flavio ^c,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PFIZER INC   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 (7 ETHYLBENZO[1,3]DIOXOL 5 YL) 1,1 DIOXO 2 (2 TRIFLUOROMETHYLPHENYL) 1,2 DIHYDRO 1 BENZO[E][1,2]THIAZINE 3 CARBOXYLIC ACID; 4 (7 ETHYLBENZO[1,3]DIOXOL 5 YL) 1,1 DIOXO 2 (2 TRIFLUOROMETHYLPHENYL) 1,2 DIHYDRO 6 BENZO[E][1,2]THIAZINE 3 CARBOXYLIC ACID; 9,11 EPITHIO 11,12 METHANOTHROMBOXANE A2; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; PD 180988; THROMBOXANE A2 DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG HALF LIFE; HEART RIGHT ATRIUM; HEMODYNAMICS; HYPOXIA; LAMB; LUNG VASOCONSTRICTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RESISTANCE BLOOD VESSEL; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BLOOD PRESSURE; CARDIAC OUTPUT; DIOXOLES; HEART RATE; HEMODYNAMIC PROCESSES; KINETICS; PULMONARY ARTERY; PULMONARY CIRCULATION; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SHEEP; TIME FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0036070756     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.302.2.672     Document Type: Article

References (40)

1. Vasodilator therapy for primary pulmonary hypertension in children
2. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
3. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension
4. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
5. Endothelin and pulmonary hypertension
6. Endothelin inhibitors
7. Low-dose nitric oxide therapy for persistent pulmonary circulation of the newborn
8. 2 constriction but not closure of ductus arteriosus
9. The endothelin-A-receptor antagonist PD180988 (CI-1034) selectively reverses the pulmonary vasoconstrictor response to hypoxia in the lamb
10. Chronic intrauterine pulmonary hypertension decreases calcium-sensitive potassium channel mRNA expression
11. Life-threatening effects of discontinuing inhaled nitric oxide in children
12. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat
13. A) receptor-selective antagonists
14. Endothelin receptor subtypes in human versus rabbit pulmonary arteries
15. Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension
16. A receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits
17. B-receptor gene expression in fetal pulmonary hypertension
18. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction
19. Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus
20. A antagonist in rats with monocrotalineinduced pulmonary hypertension
21. Role of endothelin-1 in stress response in the central nervous system
22. Impaired ventilatory responses to hypoxia and hypercapnia in mutant mice deficient in endothelin-1
23. Inhaled nitric oxide-induced rebound pulmonary hypertension: Role for endothelin-1
24. Endothelin receptor blockade attenuates air embolization-induced pulmonary hypertension in sheep
25. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia
26. Structure-activity relationships in a series of orally active α-hydroxy butenolide endothelin antagonists
27. A receptor antagonist, reduces neonatal bypoxia-induced pulmonary hypertension in piglets
28. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased blood flow
29. Synthesis of 1,1-dioxo-2,4-diphenyl-1,2-dihydrobenzothiazines: Discovery of PD 180988, a potent ETA selective antagonist
30. A receptor antagonist
31. Liquid chromatographic assay for a butenolide endothelin antagonist (PD 156707) in plasma
32. Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670 and 97-139
33. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension
34. Effects of TAK-044, a non selective endothelin receptor antagonist, on the spontaneous and indomethacin- or methylene blue-induced constriction of the ductus arteriosus in rats
35. B-receptor stimulation in experimental congenital diaphragmatic hernia
36. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
37. Isolated pulmonary resistance vessels from fetal lambs. Contractile behaviour and responses to indomethacin and endothelin-1
38. Involvement of endothelin-1 in hypoxic pulmonary vasoconstriction in the lamb
39. Endothelin receptor antagonists: Actions and rationale for their development
40. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension